CD163 and c-Met expression in the lymph node and the correlations between elevated levels of serum free light chain and the different clinicopathological parameters of advanced classical Hodgkin's lymphoma.
- Author:
Magdy BEDEWY
1
;
Shereen EL-MAGHRABY
;
Ahmed BEDEWY
Author Information
- Publication Type:Original Article
- Keywords: Hodgkin; c-Met; CD163; Free light chain
- MeSH: Biopsy; Cytokines; Hodgkin Disease; Humans; Immunohistochemistry; Leukocytosis; Light; Lymph Nodes; Lymphopenia; Risk Factors
- From:Blood Research 2013;48(2):121-127
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND: Advances in the understanding of Hodgkin's lymphoma (HL) show various functions of infiltrating immune cells and cytokines in relation to clinical outcomes. The expression of CD163 and c-Met has been suggested to have a role in lymphoid malignancy. Thus, we evaluated the expressions of CD163, c-Met, and serum free light chain (sFLC) in relation to the clinicopathological features of patients with advanced classical HL (cHL). METHODS: We assessed the expression of CD163 and c-Met in 34 patients with cHL through immunohistochemistry on the lymph node biopsy sections and the levels of pretreatment sFLC were estimated using ELISA. RESULTS: High CD163 expression correlated with increased age, B symptoms, International Prognostic Score (IPS) > or =3, mixed cellularity subtype, and low response to treatment. Further, high c-Met expression correlated with increased age at diagnosis, leukocytosis, B symptoms, and lower chance to achieve complete remission. The sFLC levels correlated with increased age at diagnosis, lymphopenia, IPS > or =3, B symptoms, and lower complete remission rates. CONCLUSION: In advanced cHL, increased expression of CD163 and c-Met showed a significant association with adverse prognostic parameters and poor response to treatment. Pretreatment high sFLC level also correlated with poor risk factors, suggesting its use as a candidate prognostic marker. A comprehensive approach for prognostic markers might represent a step towards developing a tailored therapeutic approach for HL.
